Combination therapy for advanced lung cancer with bone metastases
Treatments studied
Part of Bones, joints & muscles, Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of drugs and radiation to improve the effects of first-line chemotherapy and immunotherapy for patients with advanced non-small cell lung cancer that has spread to the bones. The goal is to help shrink tumors and potentially improve overall outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have stage IV non-small cell lung cancer (the cancer has spread to other parts of the body).
- You have bone metastases that need radiation therapy.
- You have not had any previous systemic treatment (such as chemotherapy or immunotherapy) for your lung cancer.
- You have at least one measurable tumor outside the bones that can be evaluated.
- Adenocarcinoma patients must not have certain gene mutations (EGFR, ALK, ROS-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining two immunotherapy drugs (which help your immune system fight cancer) with a type of precisely targeted radiation (SBRT) is safe and effective for people with early-stage non-small cell lung cancer. If you qualify, you might receive a treatment that could boost your body's ability to destroy cancer cells.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests whether adding radiotherapy to immunotherapy and chemotherapy can help people whose lung cancer has spread to the liver and who have already tried standard treatments. It aims to see if this combination is safe and works better at shrinking tumors.
This trial tests a new combination of treatments for advanced non-small cell lung cancer (NSCLC) that has not been treated before. It combines a type of immunotherapy (envafolimab) with a drug that may slow blood vessel growth (endostar) and a special type of radiation therapy (SRT). This may help shrink tumors and control the cancer for a longer time.
Hear when a new Stereotactic Body Radiation Therapy (SBRT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.